It’s a mixed bag when it comes to opinions on penny stocks. These tickers trading for less than $5 per share divide Wall …
Who’s next? After Gilead snapped up Immunomedics for $21 billion in September, gaining access to Trodelvy, an antibody conjugate that could be used …
Election day is just around the corner, and Wall Street is placing its bet on a Democratic sweep. Following the Presidential debate on …
A new wave of optimism is splashing onto the Street. Investment firm Goldman Sachs just gave its three-month stock forecast a boost, lifting …
When it comes to the market’s wild swings, is the glass half empty or half full? Oppenheimer’s chief investment strategist John Stoltzfus is …
Shares in Aquestive Therapeutics (AQST) plunged 37% in Friday’s after-hours trading after the U.S.
After the summer bulls, markets corrected themselves – but more than that, the selling was highly concentrated in the tech sector. The tech-heavy …
For those that thought the extreme market volatility was behind us, think again. This month, another burst of volatility was brought on by …
Was the recent market volatility just a fake out? After notching an all-time high on September 2, fears related to overheated valuations spurred …
Working the stock market is a data game. Getting the best information, in a timely way, and knowing how to use it, are …
